IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v25y2005i5p511-519.html
   My bibliography  Save this article

Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response

Author

Listed:
  • Neil Hawkins
  • Mark Sculpher

    (University of York, Centre for Health Economics, York, UK Y010 5DDmjs23@york.ac.uk.)

  • David Epstein

Abstract

When constructing decision-analytic models to evaluate the cost-effectiveness of alternative treatments, we often need to extrapolate beyond the available experimental data, as these typically relate to a limited period starting from the initiation of a new treatment or the diagnosis of the current disease state. We may also be required to extrapolate beyond the available experimental evidence to compare potential treatment sequences. Markov models are often used for this extrapolation. These models have the defining assumption that future transition probabilities are independent of past transitions. This means that, in general, transition probabilities cannot be conditional of the time spent in a given state. Where data exist to show that the risks of transition are conditional on the time spent in the treatment state, the simplifying Markov assumption can result in a loss in the model’s “face validity,†and misleading results might be generated. Several methods are available to incorporate time dependency into transition probabilities based on standard methods and software. These include the inclusion of tunnel states in Markov models and patient-level simulation, where a series of individual patients are simulated. This article considers the features and limitations of these methods and also describes a novel approach to building time dependency into a Markov model by incorporating an additional time dimension resulting in a “semi-Markov†model. An example of the implementation of such a model, using the R statistical programming language, is illustrated using a cost-effectiveness model for new epilepsy therapies.

Suggested Citation

  • Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.
  • Handle: RePEc:sae:medema:v:25:y:2005:i:5:p:511-519
    DOI: 10.1177/0272989X05280562
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X05280562
    Download Restriction: no

    File URL: https://libkey.io/10.1177/0272989X05280562?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. M. D. Stevenson & J. Oakley & J. B. Chilcott, 2004. "Gaussian Process Modeling in Conjunction with Individual Patient Simulation Modeling: A Case Study Describing the Calculation of Cost-Effectiveness Ratios for the Treatment of Established Osteoporosis," Medical Decision Making, , vol. 24(1), pages 89-100, January.
    2. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.
    3. Karl Claxton & John Posnett, 1996. "An economic approach to clinical trial design and research priority‐setting," Health Economics, John Wiley & Sons, Ltd., vol. 5(6), pages 513-524, November.
    4. Karl Claxton & John Posnett, "undated". "An Economic Approach to Clinical Trial Design and Research Priority Setting," Discussion Papers 96/19, Department of Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    2. Steven M. Teutsch & Marc L. Berger, 2005. "Evidence Synthesis and Evidence-Based Decision Making: Related But Distinct Processes," Medical Decision Making, , vol. 25(5), pages 487-489, September.
    3. Ruth A. Lewis & Dyfrig Hughes & Alex J. Sutton & Clare Wilkinson, 2021. "Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions," PharmacoEconomics, Springer, vol. 39(1), pages 25-61, January.
    4. Fernando Alarid-Escudero & Eline Krijkamp & Eva A. Enns & Alan Yang & M. G. Myriam Hunink & Petros Pechlivanoglou & Hawre Jalal, 2023. "A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example," Medical Decision Making, , vol. 43(1), pages 21-41, January.
    5. John Hornberger & Katherine Robertus, 2005. "Comprehensive Evaluations of Health Care Interventions: The Realism-Transparency Tradeoff," Medical Decision Making, , vol. 25(5), pages 490-492, September.
    6. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    7. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    8. Louise B. Russell, 2005. "Comparing Model Structures in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 25(5), pages 485-486, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of 'payback' and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357.
    2. Mark Strong & Jeremy E. Oakley & Alan Brennan, 2014. "Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample," Medical Decision Making, , vol. 34(3), pages 311-326, April.
    3. Sofia Dias & Alex J. Sutton & Nicky J. Welton & A. E. Ades, 2013. "Evidence Synthesis for Decision Making 6," Medical Decision Making, , vol. 33(5), pages 671-678, July.
    4. Samer A. Kharroubi & Alan Brennan & Mark Strong, 2011. "Estimating Expected Value of Sample Information for Incomplete Data Models Using Bayesian Approximation," Medical Decision Making, , vol. 31(6), pages 839-852, November.
    5. Stefano Conti & Karl Claxton, 2008. "Dimensions of design space: a decision-theoretic approach to optimal research design," Working Papers 038cherp, Centre for Health Economics, University of York.
    6. Simon Eckermann & Andrew Briggs & Andrew R. Willan, 2008. "Health Technology Assessment in the Cost-Disutility Plane," Medical Decision Making, , vol. 28(2), pages 172-181, March.
    7. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
    8. Afschin Gandjour, 2010. "Investment in quality improvement: how to maximize the return," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 31-42, January.
    9. Nicky J. Welton & Jason J. Madan & Deborah M. Caldwell & Tim J. Peters & Anthony E. Ades, 2014. "Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes," Medical Decision Making, , vol. 34(3), pages 352-365, April.
    10. Mark Strong & Jeremy E. Oakley & Alan Brennan & Penny Breeze, 2015. "Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample," Medical Decision Making, , vol. 35(5), pages 570-583, July.
    11. Hawre Jalal & Jeremy D. Goldhaber-Fiebert & Karen M. Kuntz, 2015. "Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling," Medical Decision Making, , vol. 35(5), pages 584-595, July.
    12. Franck Maunoury & Anastasiia Motrunich & Maria Palka-Santini & Stéphanie F Bernatchez & Stéphane Ruckly & Jean-François Timsit, 2015. "Cost-Effectiveness Analysis of a Transparent Antimicrobial Dressing for Managing Central Venous and Arterial Catheters in Intensive Care Units," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
    13. Sze Huey Tan & Keith R. Abrams & Sylwia Bujkiewicz, 2018. "Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer," Medical Decision Making, , vol. 38(7), pages 834-848, October.
    14. Ana P. Johnson-Masotti & Purushottam W. Laud & Raymond G. Hoffmann & Matthew J. Hayat & Steven D. Pinkerton, 2004. "A Bayesian Approach to Net Health Benefits: An Illustration and Application to Modeling HIV Prevention," Medical Decision Making, , vol. 24(6), pages 634-653, November.
    15. Martin E. Backhouse, 1998. "An investment appraisal approach to clinical trial design," Health Economics, John Wiley & Sons, Ltd., vol. 7(7), pages 605-619, November.
    16. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347, April.
    17. Michael Fairley & Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert, 2020. "Optimal Allocation of Research Funds under a Budget Constraint," Medical Decision Making, , vol. 40(6), pages 797-814, August.
    18. A C Bouman & A J ten Cate-Hoek & B L T Ramaekers & M A Joore, 2015. "Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
    19. Joanna Thorn & Joanna Coast & Lazaros Andronis, 2016. "Interpretation of the Expected Value of Perfect Information and Research Recommendations," Medical Decision Making, , vol. 36(3), pages 285-295, April.
    20. Hawre Jalal & Fernando Alarid-Escudero, 2018. "A Gaussian Approximation Approach for Value of Information Analysis," Medical Decision Making, , vol. 38(2), pages 174-188, February.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:25:y:2005:i:5:p:511-519. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.